ArticleBio-protocol2026
Stepwise Protocol for Alternative Splicing Analysis in Single-Cell SMART-Seq2 RNA-Seq Data.
Article in Bio-protocol, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Editorial: Technologies for RNA Detection.Bio-protocol · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA alternative splicing (AS) is an essential process that expands transcriptomic and proteomic diversity in eukaryotic cells and contributes to cellular heterogeneity across physiological and pathological conditions in humans. With the advent of single-cell RNA sequencing (scRNA-seq), it has become possible to study AS at cellular resolution, although robust and standardized analytical workflows remain to be developed. Here, we present a stepwise protocol for analyzing AS in single cells from pediatric high-grade gliomas (pHGGs) harboring the histone H3.3 lysine 27-to-methionine (H3.3K27M) mutation using SMART-Seq2 scRNA-seq data. Starting from raw sequencing reads, the workflow includes read alignment, gene-level quantification, splice junction and intron quantification, and single-nucleotide variant-based mutation detection. Gene expression-based clustering and cell-type annotation are performed by using the Seurat R package. AS analysis in tumor cells is then conducted using the MARVEL R package in combination with customized scripts to calculate percent spliced-in (PSI) values, identify variable AS events, perform dimensionality reduction, cluster cells, conduct differential AS analysis, and visualize splicing patterns. This protocol provides a reproducible and comprehensive framework for dissecting AS dynamics at single-cell resolution. It is readily adaptable to other SMART-Seq2 datasets and facilitates systematic investigation of splicing heterogeneity in diverse biological contexts. Key features • Protocol for single-cell RNA alternative splicing (AS) analysis in pediatric high-grade gliomas (pHGGs) with H3.3K27M mutation using SMART-Seq2 data. • Integrates gene expression-based clustering and genetic mutation to identify tumor populations. • MARVEL plus custom scripts enable PSI computation, variable AS detection, clustering, differential splicing analysis, and visualization of splicing patterns. • Flexible workflow applicable to other full-length scRNA-seq datasets for studying AS dynamics in cancer and development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.